➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Baxter
McKesson
Mallinckrodt
Express Scripts

Last Updated: August 3, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LEVULAN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Levulan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00524485 Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis Terminated National Cancer Institute (NCI) N/A 2005-05-01 RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis. PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.
NCT00524485 Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis Terminated Roswell Park Cancer Institute N/A 2005-05-01 RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis. PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.
NCT00706433 Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne Completed DUSA Pharmaceuticals, Inc. Phase 2 2007-03-01 The purpose of this study is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle (VEH-PDT) in subjects with moderate to severe facial acne vulgaris.
NCT00865878 ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients Terminated DUSA Pharmaceuticals, Inc. Phase 2 2009-05-01 The purpose of this study is to determine and compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) versus vehicle PDT (VEH-PDT) in the treatment of actinic keratoses (AK) and reduction of new non-melanoma skin cancer (NMSC) of the scalp or both forearms in solid organ transplant recipient subjects receiving chronic immunosuppressive therapy.
NCT01019954 Photodynamic Therapy for Early Head and Neck Tumors Completed Abramson Cancer Center of the University of Pennsylvania Phase 1 2009-01-01 This is a study to evaluate the safety and find the highest tolerable dose of Levulan® and Photodynamic Therapy (PDT) for premalignant tumors of the head and neck. Subjects will receive Levulan® by mouth and will undergo PDT. Levulan® goes throughout the body, but gets retained in cancer cells more than non-cancer cells. After 4-6 hours, the targeted area is treated with laser light which activates the Levulan® to kill the cells that contain it.
NCT01053000 Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses Completed Stewart, Roger H., M.D., P.A. N/A 2010-01-01 To determine and compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
NCT01351519 A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors Terminated MultiCare Health System Research Institute Phase 2 2011-05-01 In this study subjects will be administered a single oral dose of Aminolevulinic Acid (ALA) prior to surgical resection of their brain tumor. The ALA ultimately causes brain tumor tissue to fluoresce or light up under ultraviolet light. During surgery an ultraviolet light in the microscope chain will be turned on. The tumor tissue will fluoresce bright pink allowing the surgeon to more easily differentiate tumor tissue from normal brain tissue. The aim of the study is to determine whether ALA and fluorescent visualization of tumor tissue improves the surgeon's ability to completely resect or remove the brain tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Levulan

Condition Name

Condition Name for Levulan
Intervention Trials
Actinic Keratosis 9
Keratosis, Actinic 3
Basal Cell Nevus Syndrome 2
Non-melanoma Skin Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Levulan
Intervention Trials
Keratosis, Actinic 16
Keratosis 16
Skin Neoplasms 3
Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Levulan

Trials by Country

Trials by Country for Levulan
Location Trials
United States 84
Saudi Arabia 1
Finland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Levulan
Location Trials
California 12
Texas 9
Indiana 8
Florida 7
Minnesota 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Levulan

Clinical Trial Phase

Clinical Trial Phase for Levulan
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 11
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Levulan
Clinical Trial Phase Trials
Completed 14
Not yet recruiting 3
Active, not recruiting 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Levulan

Sponsor Name

Sponsor Name for Levulan
Sponsor Trials
DUSA Pharmaceuticals, Inc. 14
National Cancer Institute (NCI) 2
Harry T Whelan, MD 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Levulan
Sponsor Trials
Industry 15
Other 15
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
McKesson
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.